Update of the Belgian Association for the Study of the Liver Guidelines for the Treatment of Chronic Hepatitis C Genotype 1 with Protease Inhibitors
| Journal | Volume 75 - 2012 |
| Issue | Fasc.2 - Expert Point of View |
| Author(s) | Hans Orlent, Pierre Deltenre, Sven Francque, Wim Laleman, Christophe Moreno, Stefan Bourgeois, Isabelle Colle, Jean Delwaide, Stéphane De Maeght, Jean-Pierre Mulkay, Peter Stärkel, Hendrik Reynaert |
| Full article |
 VIEW FREE PDF |
| (1) Department of Gastroenterology and Hepatology, AZ St. Jan AV Brugge-Oostende, Bruges, Belgium ; (2) Service d'Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium ; (3) Department of Gastroenterology and Hepatology, University Hospital Antwerp, Belgium ; (4) Department of Liver and Biliopancreatic Disorders, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium ; (5) Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium ; (6) Department of Gastroenterology, AZ Stuivenberg, Antwerp, Belgium ; (7) Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium ; (8) Department of Gastroenterology, CHU Sart Tilman, University of Liège, Liège, Belgium ; (9) Department of Hepatogastroenterology, CHU Saint-Pierre, Brussels, Belgium ; (10) Service d'Hépatologie, Cliniques Universitaires St-Luc UCL, Woluwe, Belgium ; (11) Department of Gastroenterology and Hepatology, UZ Brussels, Brussels, Belgium. |
|
Chronic hepatitis C virus (HCV) affects approximate- ly 170 million people worldwide. Hepatitis C virus- induced cirrhosis remains the most common indication for liver transplantation and is a major contributor to the worldwide increase in the incidence of hepatocellular cancer (1). Among the six major genotypes, genotype 1 is the most common and difficult to treat. Treatment for this disease has consisted of therapies that stimulate the immune system and interfere in a nonspecific manner with viral replication. For the past decade, the standard of care for patients with chronic infection with genotype 1 HCV has been 48-week treatment of pegylated inter- feron (pegIFN) alfa and ribavirin (RBV). |
|
© Acta Gastro-Enterologica Belgica. PMID 22870791 |
